Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...

Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...

Intensifying competition, pricing pressure and copycat versions of its weight-loss drugs are holding back sales at the pharma ...

Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on ...

Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and ...

See why Novo Nordisk A/S stock is primed for a rebound despite recent declines. Click for more about NVO growth catalysts in ...

Novo Nordisk A/S downgraded after Q3 earnings and weight loss sector risks. Explore valuation, partnerships, and market ...

Novo Nordisk AS (NVO) reports robust sales and profit growth, while navigating competitive pressures and strategic ...

Metsera on Tuesday called Novo Nordisk’s new $10 billion offer “superior” to rival Pfizer's bid of $8 billion.

Another quarterly earnings announcement from Novo Nordisk and another downgrade to earnings guidance from the Danish ...